Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""Olivier, Christoph B."" wg kryterium: Autor


Wyświetlanie 1-32 z 32
Tytuł :
Triple antithrombotic therapy in cardiac patients: more questions than answers.
Autorzy :
Moser M; Heart Center, Cardiology and Angiology I, Freiburg University, Hugstetter Strasse 55, Freiburg 79106, Germany.
Olivier CB
Bode C
Pokaż więcej
Źródło :
European heart journal [Eur Heart J] 2014 Jan; Vol. 35 (4), pp. 216-23. Date of Electronic Publication: 2013 Dec 02.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Review
MeSH Terms :
Cardiovascular Diseases/*drug therapy
Fibrinolytic Agents/*therapeutic use
Administration, Oral ; Anticoagulants/administration & dosage ; Drug Administration Schedule ; Drug Therapy, Combination ; Drug-Eluting Stents ; Embolism/prevention & control ; Graft Occlusion, Vascular/prevention & control ; Hemorrhage/prevention & control ; Humans ; Percutaneous Coronary Intervention ; Practice Guidelines as Topic ; Precision Medicine ; Purinergic P2Y Receptor Antagonists/therapeutic use ; Randomized Controlled Trials as Topic ; Stroke/prevention & control ; Vitamin K/antagonists & inhibitors
Czasopismo naukowe
Tytuł :
A high ratio of ADP-TRAP induced platelet aggregation is associated more strongly with increased mortality after coronary stent implantation than high conventional ADP induced aggregation alone.
Autorzy :
Olivier CB; Cardiology and Angiology I, Heart Center Freiburg University, Hugstetter Str. 55, 79106, Freiburg, Germany, christoph.olivier@universitaets-herzzentrum.de.
Schnabel K
Brandt C
Weik P
Olschewski M
Zhou Q
Bode C
Diehl P
Moser M
Pokaż więcej
Źródło :
Clinical research in cardiology : official journal of the German Cardiac Society [Clin Res Cardiol] 2014 Dec; Vol. 103 (12), pp. 968-75. Date of Electronic Publication: 2014 Jul 16.
Typ publikacji :
Journal Article; Observational Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Myocardial Revascularization*
Stents*
Adenosine Diphosphate/*blood
Coronary Artery Disease/*surgery
Peptide Fragments/*blood
Platelet Aggregation/*physiology
Postoperative Complications/*mortality
Aged ; Coronary Artery Disease/blood ; Coronary Artery Disease/mortality ; Female ; Follow-Up Studies ; Germany/epidemiology ; Humans ; Male ; Platelet Aggregation/drug effects ; Platelet Aggregation Inhibitors/therapeutic use ; Platelet Function Tests ; Prospective Studies ; Receptors, Cell Surface ; Survival Rate/trends ; Ticlopidine/therapeutic use
Czasopismo naukowe
Tytuł :
TRAP-induced platelet aggregation is enhanced in cardiovascular patients receiving dabigatran.
Autorzy :
Olivier CB; Heart Center, Freiburg University, Cardiology and Angiology I, Freiburg-Bad Krozingen, Germany. Electronic address: Christoph.Olivier@universitaets-herzzentrum.de.
Weik P; Heart Center, Freiburg University, Cardiology and Angiology I, Freiburg-Bad Krozingen, Germany.
Meyer M; Heart Center, Freiburg University, Cardiology and Angiology I, Freiburg-Bad Krozingen, Germany.
Weber S; Center for Medical Biometry and Medical Informatics, Medical Center - University of Freiburg, Freiburg, Germany.
Anto-Michel N; Heart Center, Freiburg University, Cardiology and Angiology I, Freiburg-Bad Krozingen, Germany.
Diehl P; Heart Center, Freiburg University, Cardiology and Angiology I, Freiburg-Bad Krozingen, Germany.
Zhou Q; Heart Center, Freiburg University, Cardiology and Angiology I, Freiburg-Bad Krozingen, Germany.
Geisen U; Medical Center-University of Freiburg, Institute for Clinical Chemistry and Laboratory Medicine, Freiburg, Germany.
Bode C; Heart Center, Freiburg University, Cardiology and Angiology I, Freiburg-Bad Krozingen, Germany.
Moser M; Heart Center, Freiburg University, Cardiology and Angiology I, Freiburg-Bad Krozingen, Germany.
Pokaż więcej
Źródło :
Thrombosis research [Thromb Res] 2016 Feb; Vol. 138, pp. 63-68. Date of Electronic Publication: 2015 Nov 01.
Typ publikacji :
Journal Article; Observational Study; Research Support, Non-U.S. Gov't
MeSH Terms :
Antithrombins/*therapeutic use
Atrial Fibrillation/*drug therapy
Blood Platelets/*drug effects
Dabigatran/*therapeutic use
Platelet Aggregation/*drug effects
Receptors, Thrombin/*metabolism
Rivaroxaban/*therapeutic use
Aged ; Aged, 80 and over ; Antithrombins/pharmacology ; Dabigatran/pharmacology ; Female ; Humans ; Male ; Middle Aged ; Pulmonary Embolism/drug therapy ; Rivaroxaban/pharmacology ; Venous Thrombosis/drug therapy
Czasopismo naukowe
Tytuł :
Platelet reactivity after administration of third generation P2Y12-antagonists does not depend on body weight in contrast to clopidogrel.
Autorzy :
Olivier CB; Cardiology and Angiology I, Heart Center, Freiburg University, Hugstetter Str. 55, 79106, Freiburg - Bad Krozingen, Germany. Christoph.Olivier@universitaets-herzzentrum.de.
Schnabel K; Cardiology and Angiology I, Heart Center, Freiburg University, Hugstetter Str. 55, 79106, Freiburg - Bad Krozingen, Germany.
Weber S; Center for Medical Biometry and Medical Informatics, Medical Center - University Freiburg, Freiburg, Germany.
Zhou Q; Cardiology and Angiology I, Heart Center, Freiburg University, Hugstetter Str. 55, 79106, Freiburg - Bad Krozingen, Germany.
Bode C; Cardiology and Angiology I, Heart Center, Freiburg University, Hugstetter Str. 55, 79106, Freiburg - Bad Krozingen, Germany.
Moser M; Cardiology and Angiology I, Heart Center, Freiburg University, Hugstetter Str. 55, 79106, Freiburg - Bad Krozingen, Germany.
Diehl P; Cardiology and Angiology I, Heart Center, Freiburg University, Hugstetter Str. 55, 79106, Freiburg - Bad Krozingen, Germany.
Pokaż więcej
Źródło :
Journal of thrombosis and thrombolysis [J Thromb Thrombolysis] 2016 Jul; Vol. 42 (1), pp. 84-9.
Typ publikacji :
Journal Article
MeSH Terms :
Body Weight*
Platelet Activation/*drug effects
Purinergic P2Y Receptor Antagonists/*administration & dosage
Adenosine/administration & dosage ; Adenosine/analogs & derivatives ; Clopidogrel ; Dose-Response Relationship, Drug ; Drug Dosage Calculations ; Humans ; Platelet Aggregation/drug effects ; Prasugrel Hydrochloride/administration & dosage ; Purinergic P2Y Receptor Antagonists/pharmacology ; Purinergic P2Y Receptor Antagonists/therapeutic use ; Ticagrelor ; Ticlopidine/administration & dosage ; Ticlopidine/analogs & derivatives
Czasopismo naukowe
Tytuł :
Dabigatran and rivaroxaban do not affect AA- and ADP-induced platelet aggregation in patients receiving concomitant platelet inhibitors.
Autorzy :
Olivier CB; Cardiology and Angiology I, Heart Center, Freiburg University, Hugstetter Str. 55, 79106, Freiburg - Bad Krozingen, Germany. Christoph.Olivier@universitaets-herzzentrum.de.
Weik P; Cardiology and Angiology I, Heart Center, Freiburg University, Hugstetter Str. 55, 79106, Freiburg - Bad Krozingen, Germany.
Meyer M; Cardiology and Angiology I, Heart Center, Freiburg University, Hugstetter Str. 55, 79106, Freiburg - Bad Krozingen, Germany.
Weber S; Center for Medical Biometry and Medical Informatics, Medical Center - University of Freiburg, Freiburg, Germany.
Diehl P; Cardiology and Angiology I, Heart Center, Freiburg University, Hugstetter Str. 55, 79106, Freiburg - Bad Krozingen, Germany.
Bode C; Cardiology and Angiology I, Heart Center, Freiburg University, Hugstetter Str. 55, 79106, Freiburg - Bad Krozingen, Germany.
Moser M; Cardiology and Angiology I, Heart Center, Freiburg University, Hugstetter Str. 55, 79106, Freiburg - Bad Krozingen, Germany.
Zhou Q; Cardiology and Angiology I, Heart Center, Freiburg University, Hugstetter Str. 55, 79106, Freiburg - Bad Krozingen, Germany.
Pokaż więcej
Źródło :
Journal of thrombosis and thrombolysis [J Thromb Thrombolysis] 2016 Aug; Vol. 42 (2), pp. 161-6.
Typ publikacji :
Journal Article; Observational Study
MeSH Terms :
Dabigatran/*pharmacology
Platelet Aggregation/*drug effects
Platelet Aggregation Inhibitors/*therapeutic use
Rivaroxaban/*pharmacology
Adenosine Diphosphate/metabolism ; Antithrombins/pharmacology ; Antithrombins/therapeutic use ; Arachidonic Acid/metabolism ; Clopidogrel ; Dabigatran/therapeutic use ; Drug Therapy, Combination ; Humans ; Rivaroxaban/therapeutic use ; Ticlopidine/analogs & derivatives
Czasopismo naukowe
Tytuł :
MnTBAP increases BMPR-II expression in endothelial cells and attenuates vascular inflammation.
Autorzy :
Zhou Q; Department of Cardiology and Angiology I, Heart Center, Medical Faculty, University of Freiburg, Freiburg, Germany.
Einert M; Department of Cardiology and Angiology I, Heart Center, Medical Faculty, University of Freiburg, Freiburg, Germany.
Schmitt H; Department of Cardiology and Angiology I, Heart Center, Medical Faculty, University of Freiburg, Freiburg, Germany.
Wang Z; Department of Cardiology and Angiology I, Heart Center, Medical Faculty, University of Freiburg, Freiburg, Germany.
Pankratz F; Department of Cardiology and Angiology I, Heart Center, Medical Faculty, University of Freiburg, Freiburg, Germany.
Olivier CB; Department of Cardiology and Angiology I, Heart Center, Medical Faculty, University of Freiburg, Freiburg, Germany.
Bode C; Department of Cardiology and Angiology I, Heart Center, Medical Faculty, University of Freiburg, Freiburg, Germany.
Liao JK; Section of Cardiology, University of Chicago Medical Center, Chicago, IL, USA. Electronic address: .
Moser M; Department of Cardiology and Angiology I, Heart Center, Medical Faculty, University of Freiburg, Freiburg, Germany. Electronic address: .
Pokaż więcej
Źródło :
Vascular pharmacology [Vascul Pharmacol] 2016 Sep; Vol. 84, pp. 67-73. Date of Electronic Publication: 2016 Jul 08.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Anti-Inflammatory Agents/*pharmacology
Inflammation/*drug therapy
Metalloporphyrins/*pharmacology
Vascular Diseases/*pathology
Animals ; Bone Morphogenetic Protein Receptors, Type II/genetics ; Cell Adhesion ; Endothelial Cells/drug effects ; Endothelial Cells/metabolism ; Human Umbilical Vein Endothelial Cells ; Inflammation/pathology ; Leukocytes/metabolism ; Male ; Mice ; Mice, Inbred C57BL ; Signal Transduction/drug effects ; Smad Proteins/metabolism ; Superoxide Dismutase/metabolism ; Tumor Necrosis Factor-alpha/metabolism
Czasopismo naukowe
Tytuł :
High platelet reactivity after P2Y12-inhibition in patients with atrial fibrillation and coronary stenting.
Autorzy :
Rilinger J; Cardiology and Angiology I, Heart Center, Freiburg University, Hugstetter Str. 55, 79106, Freiburg, Germany.
Meyer M; Cardiology and Angiology I, Heart Center, Freiburg University, Hugstetter Str. 55, 79106, Freiburg, Germany.
Schnabel K; Cardiology and Angiology I, Heart Center, Freiburg University, Hugstetter Str. 55, 79106, Freiburg, Germany.
Weik P; Cardiology and Angiology I, Heart Center, Freiburg University, Hugstetter Str. 55, 79106, Freiburg, Germany.
Charlet A; Cardiology and Angiology I, Heart Center, Freiburg University, Hugstetter Str. 55, 79106, Freiburg, Germany.
Esser JS; Cardiology and Angiology I, Heart Center, Freiburg University, Hugstetter Str. 55, 79106, Freiburg, Germany.
Zhou Q; Cardiology and Angiology I, Heart Center, Freiburg University, Hugstetter Str. 55, 79106, Freiburg, Germany.
Bode C; Cardiology and Angiology I, Heart Center, Freiburg University, Hugstetter Str. 55, 79106, Freiburg, Germany.
Moser M; Cardiology and Angiology I, Heart Center, Freiburg University, Hugstetter Str. 55, 79106, Freiburg, Germany.
Diehl P; Cardiology and Angiology I, Heart Center, Freiburg University, Hugstetter Str. 55, 79106, Freiburg, Germany.
Olivier CB; Cardiology and Angiology I, Heart Center, Freiburg University, Hugstetter Str. 55, 79106, Freiburg, Germany. Christoph.Olivier@universitaets-herzzentrum.de.
Pokaż więcej
Źródło :
Journal of thrombosis and thrombolysis [J Thromb Thrombolysis] 2016 Nov; Vol. 42 (4), pp. 558-65.
Typ publikacji :
Clinical Trial; Comparative Study; Journal Article; Observational Study
MeSH Terms :
Atrial Fibrillation*/blood
Atrial Fibrillation*/therapy
Receptors, Purinergic P2Y12*
Stents*
Thromboembolism*/blood
Thromboembolism*/prevention & control
Blood Platelets/*metabolism
Platelet Activation/*drug effects
Platelet Aggregation Inhibitors/*administration & dosage
Aged ; Aged, 80 and over ; Coronary Vessels ; Drug Therapy, Combination ; Female ; Humans ; Male ; Risk Factors
Czasopismo naukowe
Tytuł :
Definitions of peri-procedural myocardial infarction and the association with one-year mortality: Insights from CHAMPION trials.
Autorzy :
Olivier CB; Stanford Center for Clinical Research (SCCR), Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Sundaram V; Quantitative Sciences Unit, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Bhatt DL; Brigham and Women's Hospital Heart & Vascular Center, Harvard Medical School, Boston, MA, USA.
Leonardi S; Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy.
Lopes RD; Duke University Medical Center, Durham, NC, USA.
Ding VY; Quantitative Sciences Unit, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Yang L; Quantitative Sciences Unit, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Stone GW; Columbia University Medical Center and the Cardiovascular Research Foundation, New York City, NY, USA.
Steg PG; FACT (French Alliance for Cardiovascular clinical Trials), DHU FIRE, INSERM Unité 1148, Université Paris-Diderot, and Hôpital Bichat, Assistance-Publique-Hôpitaux de Paris, Paris, France, and NHLI, Imperial College, Royal Brompton Hospital, London, UK.
Gibson CM; Beth Israel Deaconess Medical Center, Division of Cardiology, Boston, MA, USA.
Hamm CW; Kerckhoff Heart and Thorax Center, Bad Nauheim, Germany.
Price MJ; Scripps Clinic and Scripps Translational Science Institute, La Jolla, CA, USA.
White HD; Green Lane Cardiovascular Service, Auckland, New Zealand.
Desai M; Quantitative Sciences Unit, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Lynch DR Jr; University of Cincinnati College of Medicine, Cincinnati, OH, USA.
Harrington RA; Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Mahaffey KW; Stanford Center for Clinical Research (SCCR), Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA. Electronic address: .
Pokaż więcej
Corporate Authors :
CHAMPION PLATFORM and CHAMPION PCI Investigators
Źródło :
International journal of cardiology [Int J Cardiol] 2018 Nov 01; Vol. 270, pp. 96-101. Date of Electronic Publication: 2018 Jun 08.
Typ publikacji :
Journal Article; Randomized Controlled Trial
MeSH Terms :
Myocardial Infarction/*mortality
Myocardial Infarction/*surgery
Percutaneous Coronary Intervention/*mortality
Perioperative Care/*mortality
Cohort Studies ; Double-Blind Method ; Female ; Follow-Up Studies ; Humans ; Male ; Mortality/trends ; Myocardial Infarction/diagnosis ; Percutaneous Coronary Intervention/adverse effects ; Percutaneous Coronary Intervention/trends ; Perioperative Care/trends ; Time Factors
Czasopismo naukowe
Tytuł :
Moderate ischemic mitral regurgitation: coronary artery bypass grafting with versus without simultaneous treatment of the mitral valve.
Autorzy :
Rilinger J; Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Freiburg, Germany - .
Heilmann C; University of Cooperative Education, Plauen, Germany.
Beitinger U; Department of Cardiovascular Surgery, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Olivier CB; Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Diehl P; Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Beyersdorf F; Department of Cardiovascular Surgery, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Siepe M; Department of Cardiovascular Surgery, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Pokaż więcej
Źródło :
The Journal of cardiovascular surgery [J Cardiovasc Surg (Torino)] 2018 Dec; Vol. 59 (6), pp. 830-835. Date of Electronic Publication: 2018 Mar 12.
Typ publikacji :
Comparative Study; Journal Article; Observational Study
MeSH Terms :
Coronary Artery Bypass*/adverse effects
Coronary Artery Bypass*/mortality
Heart Valve Prosthesis Implantation*/adverse effects
Heart Valve Prosthesis Implantation*/mortality
Mitral Valve Annuloplasty*/adverse effects
Mitral Valve Annuloplasty*/mortality
Mitral Valve/*surgery
Mitral Valve Insufficiency/*surgery
Myocardial Ischemia/*surgery
Aged ; Aged, 80 and over ; Female ; Germany ; Hemodynamics ; Humans ; Male ; Middle Aged ; Mitral Valve/diagnostic imaging ; Mitral Valve/physiopathology ; Mitral Valve Insufficiency/diagnostic imaging ; Mitral Valve Insufficiency/mortality ; Mitral Valve Insufficiency/physiopathology ; Myocardial Ischemia/diagnostic imaging ; Myocardial Ischemia/mortality ; Myocardial Ischemia/physiopathology ; Retrospective Studies ; Risk Factors ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Incidence, Characteristics, and Outcomes of Myocardial Infarction in Patients With Peripheral Artery Disease: Insights From the EUCLID Trial.
Autorzy :
Olivier CB; Stanford Center for Clinical Research, Department of Medicine, Stanford University School of Medicine, Stanford, California.
Mulder H; Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina.
Hiatt WR; Division of Cardiology, University of Colorado School of Medicine, Aurora.; CPC Clinical Research, University of Colorado School of Medicine, Aurora.
Jones WS; Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina.
Fowkes FGR; Usher Institute of Population Health Sciences and Informatics, University of Edinburgh, Edinburgh, United Kingdom.
Rockhold FW; Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina.
Berger JS; Department of Medicine, New York University School of Medicine, New York.; Department of Surgery, New York University School of Medicine, New York.
Baumgartner I; Swiss Cardiovascular Center, Inselspital, University of Bern, Bern, Switzerland.
Held P; AstraZeneca Gothenburg, Mölndal, Sweden.
Katona BG; AstraZeneca Gaithersburg, Gaithersburg, Maryland.
Norgren L; Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
Blomster J; Turku University Hospital, Turku, Finland.
Patel MR; Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina.
Mahaffey KW; Stanford Center for Clinical Research, Department of Medicine, Stanford University School of Medicine, Stanford, California.
Pokaż więcej
Źródło :
JAMA cardiology [JAMA Cardiol] 2019 Jan 01; Vol. 4 (1), pp. 7-15.
Typ publikacji :
Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
MeSH Terms :
Extremities/*blood supply
Myocardial Infarction/*epidemiology
Peripheral Arterial Disease/*complications
Aged ; Ankle Brachial Index/methods ; Clopidogrel/therapeutic use ; Coronary Artery Bypass/methods ; Death ; Extremities/pathology ; Female ; Hospitalization ; Humans ; Incidence ; Ischemia ; Male ; Middle Aged ; Myocardial Infarction/classification ; Myocardial Infarction/mortality ; Myocardial Infarction/therapy ; Percutaneous Coronary Intervention/methods ; Peripheral Arterial Disease/drug therapy ; Peripheral Arterial Disease/therapy ; Platelet Aggregation Inhibitors/therapeutic use ; Risk Factors ; Ticagrelor/therapeutic use
Czasopismo naukowe
Tytuł :
Supplemental_Digital_Content - Appropriateness of Direct Oral Anticoagulant Dosing in Patients With Atrial Fibrillation: Insights From the Veterans Health Administration
Autorzy :
Leef, George C.
Perino, Alexander C.
Askari, Mariam
Fan, Jun
P. Michael Ho
Olivier, Christoph B.
Longo, Lisa
Mahaffey, Kenneth W.
Mintu P. Turakhia
Pokaż więcej
Temat :
111599 Pharmacology and Pharmaceutical Sciences not elsewhere classified
111199 Nutrition and Dietetics not elsewhere classified
humanities
111702 Aged Health Care
Tytuł :
Central Adjudication Identified Additional and Prognostically Important Myocardial Infarctions in Patients Undergoing Percutaneous Coronary Intervention.
Autorzy :
Olivier CB; Stanford Center for Clinical Research, Department of Medicine, Stanford University School of Medicine, CA (C.B.O., K.W.M.).; Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Germany (C.B.O.).
Bhatt DL; Brigham and Women's Hospital Heart & Vascular Center, Harvard Medical School, Boston, MA (D.L.B.).
Leonardi S; University of Pavia, Fondazione IRCCS Policlinico S. Matteo, Pavia, Italy (S.L.).
Stone GW; Columbia University Medical Center and the Cardiovascular Research Foundation, New York City, NY (G.W.S.).
Gibson CM; Beth Israel Deaconess Medical Center, Division of Cardiology, Boston, MA (C.M.G.).
Steg PG; FACT (French Alliance for Cardiovascular Clinical Trials), DHU FIRE, INSERM Unité 1148, Université Paris-Diderot, and Hôpital Bichat, Assistance-Publique-Hôpitaux de Paris, Paris, France, and NHLI, Imperial College, Royal Brompton Hospital, London, United Kingdom (P.G.S.).
Hamm CW; Kerckhoff Heart and Thorax Center, Bad Nauheim, Germany (C.W.H.).
Wilson MD; Duke University Medical Center, Durham, NC (M.D.W., S.M., R.D.L.).
Mangum S; Duke University Medical Center, Durham, NC (M.D.W., S.M., R.D.L.).
Price MJ; Scripps Clinic and Scripps Translational Science Institute, La Jolla, CA (M.J.P.).
Prats J; Elysis Llc, Carlisle, MA (J.P.).
White HD; Green Lane Cardiovascular Service, Auckland, New Zealand (H.D.W.).
Lopes RD; Duke University Medical Center, Durham, NC (M.D.W., S.M., R.D.L.).
Harrington RA; Department of Medicine, Stanford University School of Medicine, Stanford, CA (R.A.H.).
Mahaffey KW; Stanford Center for Clinical Research, Department of Medicine, Stanford University School of Medicine, CA (C.B.O., K.W.M.).
Pokaż więcej
Corporate Authors :
CHAMPION PHOENIX Investigators *
Źródło :
Circulation. Cardiovascular interventions [Circ Cardiovasc Interv] 2019 Jul; Vol. 12 (7), pp. e007342. Date of Electronic Publication: 2019 Jul 12.
Typ publikacji :
Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
MeSH Terms :
Research Design*
Adenosine Monophosphate/*analogs & derivatives
Coronary Artery Disease/*therapy
Coronary Thrombosis/*prevention & control
Myocardial Infarction/*prevention & control
Percutaneous Coronary Intervention/*adverse effects
Platelet Aggregation Inhibitors/*therapeutic use
Adenosine Monophosphate/adverse effects ; Adenosine Monophosphate/therapeutic use ; Coronary Artery Disease/complications ; Coronary Artery Disease/diagnosis ; Coronary Artery Disease/mortality ; Coronary Thrombosis/diagnosis ; Coronary Thrombosis/etiology ; Coronary Thrombosis/mortality ; Humans ; Myocardial Infarction/diagnosis ; Myocardial Infarction/etiology ; Myocardial Infarction/mortality ; Percutaneous Coronary Intervention/mortality ; Platelet Aggregation Inhibitors/adverse effects ; Randomized Controlled Trials as Topic ; Risk Assessment ; Risk Factors ; Time Factors ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Site Variation and Outcomes for Antithrombotic Therapy in Atrial Fibrillation Patients After Percutaneous Coronary Intervention.
Autorzy :
Olivier CB; Department of Medicine, Stanford Center for Clinical Research (C.B.O., K.W.M.), Stanford University School of Medicine, CA.; Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Germany (C.B.O.).
Fan J; Division of Cardiology, Veterans Affairs Palo Alto Health Care System, CA (J.F., M.A., P.A.H., A.C.P., G.C.L., M.P.T.).
Askari M; Division of Cardiology, Veterans Affairs Palo Alto Health Care System, CA (J.F., M.A., P.A.H., A.C.P., G.C.L., M.P.T.).
Mahaffey KW; Department of Medicine, Stanford Center for Clinical Research (C.B.O., K.W.M.), Stanford University School of Medicine, CA.
Heidenreich PA; Department of Medicine (P.A.H., A.C.P., G.C.L., R.A.H., M.P.T.), Stanford University School of Medicine, CA.; Division of Cardiology, Veterans Affairs Palo Alto Health Care System, CA (J.F., M.A., P.A.H., A.C.P., G.C.L., M.P.T.).
Perino AC; Department of Medicine (P.A.H., A.C.P., G.C.L., R.A.H., M.P.T.), Stanford University School of Medicine, CA.; Division of Cardiology, Veterans Affairs Palo Alto Health Care System, CA (J.F., M.A., P.A.H., A.C.P., G.C.L., M.P.T.).
Leef GC; Department of Medicine (P.A.H., A.C.P., G.C.L., R.A.H., M.P.T.), Stanford University School of Medicine, CA.; Division of Cardiology, Veterans Affairs Palo Alto Health Care System, CA (J.F., M.A., P.A.H., A.C.P., G.C.L., M.P.T.).
Ho PM; Division of Cardiology, Denver VA Medical Center, CO (P.M.H.).
Harrington RA; Department of Medicine (P.A.H., A.C.P., G.C.L., R.A.H., M.P.T.), Stanford University School of Medicine, CA.; Department of Medicine, Center for Digital Health (R.A.H., M.P.T.), Stanford University School of Medicine, CA.
Turakhia MP; Department of Medicine (P.A.H., A.C.P., G.C.L., R.A.H., M.P.T.), Stanford University School of Medicine, CA.; Department of Medicine, Center for Digital Health (R.A.H., M.P.T.), Stanford University School of Medicine, CA.; Division of Cardiology, Veterans Affairs Palo Alto Health Care System, CA (J.F., M.A., P.A.H., A.C.P., G.C.L., M.P.T.).
Pokaż więcej
Źródło :
Circulation. Cardiovascular interventions [Circ Cardiovasc Interv] 2019 Aug; Vol. 12 (8), pp. e007604. Date of Electronic Publication: 2019 Aug 16.
Typ publikacji :
Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.
MeSH Terms :
Percutaneous Coronary Intervention*/adverse effects
Percutaneous Coronary Intervention*/mortality
Anticoagulants/*administration & dosage
Atrial Fibrillation/*drug therapy
Coronary Artery Disease/*therapy
Fibrinolytic Agents/*administration & dosage
Healthcare Disparities/*trends
Platelet Aggregation Inhibitors/*administration & dosage
Practice Patterns, Physicians'/*trends
Purinergic P2Y Receptor Antagonists/*administration & dosage
Stroke/*prevention & control
Aged ; Anticoagulants/adverse effects ; Atrial Fibrillation/diagnosis ; Atrial Fibrillation/mortality ; Coronary Artery Disease/diagnosis ; Coronary Artery Disease/mortality ; Drug Utilization/trends ; Female ; Fibrinolytic Agents/adverse effects ; Hemorrhage/chemically induced ; Hemorrhage/epidemiology ; Humans ; Male ; Middle Aged ; Platelet Aggregation Inhibitors/adverse effects ; Purinergic P2Y Receptor Antagonists/adverse effects ; Retrospective Studies ; Risk Assessment ; Risk Factors ; Stroke/diagnosis ; Stroke/mortality ; Time Factors ; Treatment Outcome ; United States/epidemiology ; United States Department of Veterans Affairs ; Veterans Health
Czasopismo naukowe
Tytuł :
Is Bleeding Always Bad?: Bad Boy Bleeding.
Autorzy :
Bode C; Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Germany. Electronic address: christoph..
Olivier CB; Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Germany.
Duerschmied D; Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Germany.
Pokaż więcej
Źródło :
Journal of the American College of Cardiology [J Am Coll Cardiol] 2019 Sep 24; Vol. 74 (12), pp. 1529-1531.
Typ publikacji :
Editorial; Comment
MeSH Terms :
Peripheral Arterial Disease*
Rivaroxaban*
Aspirin ; Factor Xa Inhibitors ; Hemorrhage ; Humans ; Male
Opinia redakcyjna
Tytuł :
Anticoagulation and anaemia: old opponents from the era of VKA?
Autorzy :
Bode C; Department of Cardiology and Angiology I, Heart Center, University of Freiburg, Freiburg, Germany.
Olivier CB; Department of Cardiology and Angiology I, Heart Center, University of Freiburg, Freiburg, Germany.
Duerschmied D; Department of Cardiology and Angiology I, Heart Center, University of Freiburg, Freiburg, Germany.
Pokaż więcej
Źródło :
European heart journal [Eur Heart J] 2019 Dec 07; Vol. 40 (46), pp. 3791-3792.
Typ publikacji :
Editorial; Comment
MeSH Terms :
Anemia*
Atrial Fibrillation*
Anticoagulants ; Cohort Studies ; Humans ; Vitamin K
Opinia redakcyjna
Tytuł :
A double-blind, randomized, placebo-controlled pilot trial to evaluate safety and efficacy of vorapaxar on arteriovenous fistula maturation.
Autorzy :
Olivier CB; Stanford Center for Clinical Research (SCCR), Department of Medicine, School of Medicine, Stanford University, Stanford, CA, USA.; Department of Cardiology and Angiology I, Faculty of Medicine, Heart Center, University of Freiburg, Freiburg, Germany.
Sundaram V; Quantitative Sciences Unit, Department of Medicine, School of Medicine, Stanford University, Stanford, CA, USA.
Chertow GM; Division of Nephrology, School of Medicine, Stanford University, Stanford, CA, USA.
Shashidhar S; Stanford Center for Clinical Research (SCCR), Department of Medicine, School of Medicine, Stanford University, Stanford, CA, USA.
McDonnell LK; Division of Vascular Surgery, School of Medicine, Stanford University, Stanford, CA, USA.
Ding VY; Quantitative Sciences Unit, Department of Medicine, School of Medicine, Stanford University, Stanford, CA, USA.
Desai M; Quantitative Sciences Unit, Department of Medicine, School of Medicine, Stanford University, Stanford, CA, USA.
Mahaffey KW; Stanford Center for Clinical Research (SCCR), Department of Medicine, School of Medicine, Stanford University, Stanford, CA, USA.
Mell M; Division of Vascular Surgery, School of Medicine, Stanford University, Stanford, CA, USA.; Division of Vascular Surgery, University of California at Davis, Sacramento, CA, USA.
Pokaż więcej
Źródło :
The journal of vascular access [J Vasc Access] 2020 Jul; Vol. 21 (4), pp. 467-474. Date of Electronic Publication: 2019 Nov 27.
Typ publikacji :
Journal Article; Randomized Controlled Trial
MeSH Terms :
Arteriovenous Shunt, Surgical*/adverse effects
Renal Dialysis*/adverse effects
Kidney Failure, Chronic/*therapy
Lactones/*therapeutic use
Platelet Aggregation Inhibitors/*therapeutic use
Pyridines/*therapeutic use
Upper Extremity/*blood supply
Aged ; California ; Double-Blind Method ; Early Termination of Clinical Trials ; Female ; Hemorrhage/chemically induced ; Humans ; Kidney Failure, Chronic/diagnosis ; Lactones/adverse effects ; Male ; Middle Aged ; Pilot Projects ; Platelet Aggregation Inhibitors/adverse effects ; Pyridines/adverse effects ; Receptor, PAR-1/antagonists & inhibitors ; Risk Factors ; Time Factors ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Dual-Pathway Antithrombotic Therapy in Patients With Atrial Fibrillation After Percutaneous Coronary Intervention in Stable Coronary Artery Disease: A Single-Center, Single-Operator, Retrospective Cohort Study.
Autorzy :
Heger LA; Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Danzer M; Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Bode C; Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Hortmann M; Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Duerschmied D; Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Olivier CB; Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Moser M; Department of Cardiology and Angiology I, Heart Center Freiburg University, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Pokaż więcej
Źródło :
Frontiers in medicine [Front Med (Lausanne)] 2020 Sep 30; Vol. 7, pp. 414. Date of Electronic Publication: 2020 Sep 30 (Print Publication: 2020).
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Appropriateness of Direct Oral Anticoagulant Dosing in Patients With Atrial Fibrillation: Insights From the Veterans Health Administration.
Autorzy :
Leef GC; Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.; Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, USA.
Perino AC; Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.; Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, USA.
Askari M; Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, USA.
Fan J; Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, USA.
Ho PM; Veterans Affairs Eastern Colorado Health Care System, Denver, CO, USA.; University of Colorado School of Medicine, Denver, CO, USA.
Olivier CB; Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Longo L; Department of Veteran Affairs, Pharmacy Benefits Management Services, USA.
Mahaffey KW; Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.; Stanford Center for Clinical Research, Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.
Turakhia MP; Department of Medicine, Stanford University School of Medicine, Stanford, CA, USA.; Veterans Affairs Palo Alto Health Care System, Palo Alto, CA, USA.; Center for Digital Health, Stanford University School of Medicine, Stanford, CA, USA.
Pokaż więcej
Źródło :
Journal of pharmacy practice [J Pharm Pract] 2020 Oct; Vol. 33 (5), pp. 647-653. Date of Electronic Publication: 2019 Feb 21.
Typ publikacji :
Journal Article
MeSH Terms :
Atrial Fibrillation*/diagnosis
Atrial Fibrillation*/drug therapy
Stroke*/drug therapy
Administration, Oral ; Aged ; Anticoagulants/therapeutic use ; Cohort Studies ; Humans ; Retrospective Studies ; Veterans Health
Czasopismo naukowe
Tytuł :
Antithrombotische Therapie nach strukturellen kardialen Interventionen: Empfehlung der Arbeitsgruppe Kardiovaskuläre Hämostase und Antithrombotische Therapie (AG19) der Deutschen Gesellschaft für Kardiologie – Herz- und Kreislaufforschung e. V. (DGK) in Zusammenarbeit mit der Arbeitsgruppe Interventionelle Kardiologie (AG6) – AGIK und der Arbeitsgruppe Klinische Pharmakologie (AG22) der DGK (German)
Autorzy :
Hochholzer, Willibald
Nührenberg, Thomas
Flierl, Ulrike
Olivier, Christoph B.
Landmesser, Ulf
Möllmann, Helge
Dörr, Marcus
Mehilli, Julinda
Schäfer, Andreas
Dürschmied, Daniel
Sibbing, Dirk
El-Armouche, Ali
Zeymer, Uwe
Neumann, Franz-Josef
Ahrens, Ingo
Geisler, Tobias
Pokaż więcej
Alternatywny tytuł :
Antithrombotic therapy after structural cardiac interventions: Recommendations of the Working Group on Cardiovascular Hemostasis and Antithrombotic Therapy (AG19) of the German Cardiac Society (DGK) in cooperation with the Working Group on Interventional Cardiology (AG6, AGIK) and the Working Group on Clinical Pharmacology (AG22) of the DGK (English)
Źródło :
Der Kardiologe; Feb2021, Vol. 15 Issue 1, p57-70, 14p
Czasopismo naukowe
    Wyświetlanie 1-32 z 32

    Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies